multiple sclerosis

Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
Celgene Corporation
multiple sclerosis
ozanimod
Flag link:
Lemtrada Treatment Effects in MS Patients Maintained Over Seven Years
Lemtrada
Sanofi
Relapsing Remitting Multiple Sclerosis
multiple sclerosis
Flag link:
Roche Acquires MS Remyelination Program from Versant Ventures
Roche Acquires MS Remyelination Program from Versant Ventures
CP Wire
Roche
MS
multiple sclerosis
remylination
M&A
Versant Ventures
Inception 5
Flag link:
Roche Acquires MS Remyelination Program from Versant Ventures
Roche
Versant Ventures
multiple sclerosis
Flag link:
Novartis' Siponimod significantly improved outcomes in PhIII data published in Lancet
Novartis' Siponimod significantly improved outcomes in PhIII data published in Lancet
CP Wire
Novartis
siponimod
clinical trials
MS
multiple sclerosis
SPMS
Flag link:
Biogen, AbbVie yank MS drug Zinbryta off the market in the wake of encephalitis cases
Biogen, AbbVie yank MS drug Zinbryta off the market in the wake of encephalitis cases
Endpoints
Biogen
AbbVie
MS
multiple sclerosis
Zinbryta
Europe
encephalitis
Flag link:
Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future
Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future
Stat
Celgene
FDA
MS
multiple sclerosis
ozanimod
Flag link:
Novartis, Momenta grab a delayed FDA OK for blockbuster Copaxone knockoff
Novartis, Momenta grab a delayed FDA OK for blockbuster Copaxone knockoff
Endpoints
Novartis
Momenta Pharmaceuticals
FDA
Copaxone
Teva Pharmaceutical
Glatopa
MS
multiple sclerosis
Flag link:
Will Teva Pharmaceutical's Pain Be Mylan's Gain?
Will Teva Pharmaceutical's Pain Be Mylan's Gain?
Motley Fool
Teva Pharmaceutical
Mylan Labs
Copaxone
generics
MS
multiple sclerosis
Flag link:
Multiple Sclerosis Drug Could be Safer for Patients if Dosing Intervals are Extended, Says Study
Multiple Sclerosis Drug Could be Safer for Patients if Dosing Intervals are Extended, Says Study
Xtalks
MS
multiple sclerosis
dosing
PML
Flag link:
Roche granted approval for ocrelizumab (multiple sclerosis) in Europe
Roche granted approval for ocrelizumab (multiple sclerosis) in Europe
GoinPharma
Roche
ocrelizumab
Europe
MS
multiple sclerosis
Flag link:
Look out, Teva: Mylan's Copaxone copy has already captured serious share
Look out, Teva: Mylan's Copaxone copy has already captured serious share
Fierce Pharma
Teva Pharmaceutical
Mylan Labs
Copaxone
generics
MS
multiple sclerosis
Flag link:
Biogen set to raise $300M from New Year's price hikes, just enough to offset MS competition
Biogen set to raise $300M from New Year's price hikes, just enough to offset MS competition
Fierce Pharma
Biogen
MS
multiple sclerosis
drug pricing
Flag link:
Biogen inks outcomes-based contract for MS meds
Biogen inks outcomes-based contract for MS meds
BioPharma Dive
Biogen
MS
multiple sclerosis
Prime Therapeutics
PBMs
Flag link:
Most Impressive Drug Launch: Roche's Ocrevus
Most Impressive Drug Launch: Roche's Ocrevus
BioPharma Dive
Roche
Ocrevus
drug launches
MS
multiple sclerosis
Flag link:
Alkermes shares rise 6% on Biogen multiple sclerosis drug partnership
Alkermes shares rise 6% on Biogen multiple sclerosis drug partnership
Marketwatch
Alkermes
Biogen
MS
multiple sclerosis
ALKS 8700
Flag link:
Sanofi bolsters its position on multiple sclerosis with a $765M BTK licensing deal
Sanofi bolsters its position on multiple sclerosis with a $765M BTK licensing deal
Endpoints
Sanofi
multiple sclerosis
MS
Principia Biopharma
Flag link:
How Aubagio became the most switched-to oral MS drug
How Aubagio became the most switched-to oral MS drug
Medical Marketing and Media
Aubagio
MS
multiple sclerosis
Sanofi
Flag link:
Late-stage ozanimod data brings Celgene closer to filing
Late-stage ozanimod data brings Celgene closer to filing
BioPharma Dive
ozanimod
Celgene
MS
multiple sclerosis
Flag link:
Bloodied Celgene posts promising ozanimod PhIII MS data, but is it really a $6 billion drug?
Bloodied Celgene posts promising ozanimod PhIII MS data, but is it really a $6 billion drug?
Endpoints
Celgene
ozaminod
MS
multiple sclerosis
Flag link:

Pages